ATE123225T1 - Synthese von menschlichen virusantigenen durch hefe. - Google Patents

Synthese von menschlichen virusantigenen durch hefe.

Info

Publication number
ATE123225T1
ATE123225T1 AT89110270T AT89110270T ATE123225T1 AT E123225 T1 ATE123225 T1 AT E123225T1 AT 89110270 T AT89110270 T AT 89110270T AT 89110270 T AT89110270 T AT 89110270T AT E123225 T1 ATE123225 T1 AT E123225T1
Authority
AT
Austria
Prior art keywords
yeast
hbsag
synthesis
purified
particles
Prior art date
Application number
AT89110270T
Other languages
English (en)
Inventor
William J Rutter
Pablo D T Valenzuela
Benjamin D Hall
Gustav Ammerer
Original Assignee
Univ California
Washington Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23113710&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE123225(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ California, Washington Res Found filed Critical Univ California
Application granted granted Critical
Publication of ATE123225T1 publication Critical patent/ATE123225T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT89110270T 1981-08-04 1982-08-04 Synthese von menschlichen virusantigenen durch hefe. ATE123225T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US28991581A 1981-08-04 1981-08-04

Publications (1)

Publication Number Publication Date
ATE123225T1 true ATE123225T1 (de) 1995-06-15

Family

ID=23113710

Family Applications (1)

Application Number Title Priority Date Filing Date
AT89110270T ATE123225T1 (de) 1981-08-04 1982-08-04 Synthese von menschlichen virusantigenen durch hefe.

Country Status (12)

Country Link
EP (1) EP0072318B1 (de)
JP (1) JPS5877823A (de)
AT (1) ATE123225T1 (de)
CA (1) CA1341642C (de)
DE (2) DE3280468T2 (de)
DK (2) DK163931C (de)
ES (1) ES514712A0 (de)
GR (1) GR76274B (de)
HK (1) HK64591A (de)
IE (1) IE65996B1 (de)
PT (1) PT75374B (de)
SG (1) SG58191G (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ201705A (en) * 1981-08-31 1986-03-14 Genentech Inc Recombinant dna method for production of hepatitis b surface antigen in yeast
JPS58146281A (ja) * 1981-10-19 1983-08-31 Suntory Ltd 酵母細胞の形質転換法
DE3381566D1 (de) * 1982-08-16 1990-06-21 Agency Science & Tech Hepatitis-b-virus-gen enthaltendes rekombinantes plasmid, mit diesem rekombinanten plasmid transformierte hefe und herstellung von hepatitis-b-virus-oberflaechenantigen.
IL69202A (en) * 1982-09-08 1991-08-16 Smith Kline Rit Surface antigen polypeptides of hbv virus produced in yeast and the preparation thereof
US4876197A (en) * 1983-02-22 1989-10-24 Chiron Corporation Eukaryotic regulatable transcription
CA1341302C (en) * 1983-02-22 2001-10-09 Rae Lyn Burke Yeast expression systems with vectors having gapdh or pyk promoters and synthesis of foreign protein
JPS6078999A (ja) * 1983-10-05 1985-05-04 Chemo Sero Therapeut Res Inst ＨＢｓ抗原の精製方法
JPS60104020A (ja) * 1983-10-14 1985-06-08 メルク　エンド　カムパニー　インコーポレーテツド Ａ型肝炎‐タンパク質サブユニツト抗原
ATE102250T1 (de) * 1984-05-11 1994-03-15 Chiron Corp Erhoehte hefetranskription unter verwendung einer hybridkonstruktion der promotorregion.
ATE73349T1 (de) * 1984-06-18 1992-03-15 Chiron Corp Hepatitisoberflaechenantigenpartikelvakzin.
US4624918A (en) * 1984-07-09 1986-11-25 Genentech, Inc. Purification process for hepatitis surface antigen and product thereof
US4722840A (en) * 1984-09-12 1988-02-02 Chiron Corporation Hybrid particle immunogens
EP0175261B1 (de) * 1984-09-12 1991-12-11 Chiron Corporation Hybridpartikel-Immunogene
EP0225887B1 (de) * 1985-04-08 1994-06-08 Amgen Inc. Verfahren und hybridpromotor zur steuerung der exogenen gentranskription
US4649192A (en) * 1985-05-30 1987-03-10 Smith Kline-Rit Method for the isolation and purification of hepatitis B surface antigen using polysorbate
DE3687523T2 (de) * 1985-08-15 1993-05-13 Amgen Inc Gaerverfahren zur herstellung von hepatitisimpfstoff.
JP2810364B2 (ja) * 1985-10-04 1998-10-15 ジ・アップジョン・カンパニー 偽狂犬病ウイルス蛋白質
US4935349A (en) * 1986-01-17 1990-06-19 Zymogenetics, Inc. Expression of higher eucaryotic genes in aspergillus
US4816564A (en) * 1986-01-31 1989-03-28 Merck & Co., Inc. Method for producing hepatitis B virus proteins in yeast
JPH0768267B2 (ja) * 1986-06-05 1995-07-26 財団法人阪大微生物病研究会 フラビウイルス抗原
JPH089637B2 (ja) * 1986-06-18 1996-01-31 財団法人阪大微生物病研究会 Ｂ型肝炎ウイルス抗原とその製造法
JPH0789951B2 (ja) * 1986-06-18 1995-10-04 財団法人阪大微生物病研究会 遺伝子発現産物の精製法
IL79740A0 (en) * 1986-08-17 1986-11-30 Yeda Res & Dev Hepatitis vaccine
HUT50875A (en) * 1986-11-01 1990-03-28 Oxford Gene Systems Ltd Process for producing particular hybrid hiv antigenes
DE3882154T2 (de) * 1987-02-27 1993-12-02 Merck & Co Inc Verfahren zur Herstellung des pres 1/S2/S-Hepatitis-B-Antigens aus Hefe.
US5026828A (en) * 1987-02-27 1991-06-25 Merck & Co., Inc. Method of purifying recombinant pres-1/S-2/S/S hepatitis B antigen from yeast
EP0299242A3 (de) * 1987-06-22 1989-01-25 Medico Labs Ag Heterologe, virale, immunogen wirksame Peptidpartikel
US5011915A (en) * 1987-10-26 1991-04-30 Merck & Co., Inc. Process for purifying recombinant hepatitis antigens
IL90161A0 (en) * 1988-05-13 1989-12-15 Phillips Petroleum Co Expression of hepatitis b s and pres2 proteins in methylotrophic yeasts
EP0491077A1 (de) * 1990-12-19 1992-06-24 Medeva Holdings B.V. Zusammensetzung verwendbar als therapeutisches Mittel gegen chronische virale Leberkrankheiten

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2270892A1 (en) * 1974-05-14 1975-12-12 Inst Francais D Immunologie Vaccines from attenuated viruses - which have been serially incubated with yeast cells, especially Saccharomyces cerevisiae
FI86437C (fi) * 1978-12-22 1992-08-25 Biogen Inc Foerfarande foer framstaellning av polypeptider med de antigena egenskaperna hos ett hepatitis b- virusantigen.
IE52036B1 (en) * 1979-05-24 1987-05-27 Univ California Non-passageable viruses
FR2480780B1 (fr) * 1980-04-22 1985-12-06 Pasteur Institut Procede de transformation de cellules, notamment eucaryotes, par un adn circulaire tel que celui du virus de l'hepatite b et preparations contenant les produits d'expression desdits adn
JPH0314840A (ja) * 1988-12-28 1991-01-23 Kureha Chem Ind Co Ltd 弗化ビニリデン系ポリマー二軸冷延伸フィルムおよびその製造方法

Also Published As

Publication number Publication date
HK64591A (en) 1991-08-23
ES8400877A1 (es) 1983-11-16
EP0072318B1 (de) 1990-05-30
JPS5877823A (ja) 1983-05-11
ES514712A0 (es) 1983-11-16
PT75374B (en) 1985-12-13
IE65996B1 (en) 1995-11-29
SG58191G (en) 1993-02-19
EP0072318A3 (en) 1983-03-16
DK114791A (da) 1991-06-14
DK163931C (da) 1992-09-14
DE3280468D1 (de) 1995-07-06
JPH0526798B2 (de) 1993-04-19
CA1341642C (en) 2023-02-21
DE3280468T2 (de) 1995-12-07
DK347682A (da) 1983-02-05
GR76274B (de) 1984-08-04
DK114791D0 (da) 1991-06-14
PT75374A (en) 1982-09-01
DE3280186D1 (de) 1990-07-05
EP0072318A2 (de) 1983-02-16
DK169152B1 (da) 1994-08-29
DK163931B (da) 1992-04-21

Similar Documents

Publication Publication Date Title
DE3280468D1 (de) Synthese von menschlichen Virusantigenen durch Hefe.
IL95153A0 (en) Novel antigens and their production
KR880009130A (ko) 간염 b 바이러스 표면항원 및 이를 함유하는 하이브리드 항원
EP0291586A3 (de) Rekombinantes Hepatitis-B-Oberflächenantigen und dieses enthaltender Impfstoff
KR920007683B1 (ko) HBs항원의 정제방법
PL279426A1 (en) Method of intensifying generation of antigenic hbv particles containing essentially s and pre s2 proteins
ATE91718T1 (de) Rekombinante dns-molekuele die hepatitis-boberfl|chenantigenkodieren, deren herstellung und abgeleitete vakzine.
EP0248410A3 (de) Hefe-Promotor und Verfahren zur Herstellung von heterologen Proteinen
ATE53235T1 (de) Synthese von menschlichen viralen antigenen mit hilfe von hefe.
EP0105141A3 (de) Rekombinante DNS Moleküle, Verfahren zu deren Herstellung, deren Verwendung zur Herstellung von Hepatitis B Oberflächen-Antigen (HBsAg) und pharmazeutische Zusammensetzungen die das HBsAg enthalten
KR850700214A (ko) B형 간염비루스 표면항원과 중합된 인체혈청 알부민의 수용체를 지니는 입자를 함유하는, 백신의 제조에 유용한 조성물 및 그 입자생산성의 동물세포와 그 세포의 획득방법
DE3750330T2 (de) Verfahren zur Herstellung eines Impfstoffs gegen Hepatitis B.
Stephenne Production in yeast and mammalian cells of the first recombinant DNA human vaccine against hepatitis B: A technical and immunological comparison.
JPH0762033B2 (ja) Ｂ型肝炎ワクチン
JPS57209298A (en) Recombinant dna, its preparation, and host transformed therewith
MY106731A (en) Novel antigens and methods therefor

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EELA Cancelled due to lapse of time